ID   KMS-28PE
AC   CVCL_2995
SY   KMS-28-PE; KMS28PE; Kawasaki Medical School-28-Pleural Effusion
DR   EFO; EFO_0006618
DR   ArrayExpress; E-MTAB-2706
DR   cancercelllines; CVCL_2995
DR   Cell_Model_Passport; SIDM01656
DR   Cell_Model_Passport; SIDM01797
DR   CGH-DB; 33-1
DR   CGH-DB; 9144-4
DR   Cosmic; 2081428
DR   Cosmic; 2081440
DR   Cosmic; 2367289
DR   DepMap; ACH-001541
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM621589
DR   JCRB; JCRB1191
DR   JCRB; NIHS0489
DR   Lonza; 1429
DR   PharmacoDB; KMS28PE_771_2019
DR   Progenetix; CVCL_2995
DR   Wikidata; Q54900178
RX   CelloPub=CLPUB00604;
RX   PubMed=15215163;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=25485619;
RX   PubMed=26589293;
RX   PubMed=32123307;
WW   Info; Keats Lab; -; https://www.keatslab.org/myeloma-cell-lines
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   HLA typing: A*24:02,24:02; B*40:02,52:01; C*03:04,12:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Homozygous (DepMap=ACH-001541).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly105Arg (c.313G>C); ClinVar=VCV000406574; Zygosity=Homozygous (DepMap=ACH-001541).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; Array-based CGH.
CC   Omics: Variations; SNP array analysis.
CC   Discontinued: JCRB; NIHS0489; true.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
CC   Cell type: Plasma cell; CL=CL_0000786.
ST   Source(s): DepMap=ACH-001541; JCRB=JCRB1191
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 9,11
ST   D18S51: 14,15
ST   D21S11: 30
ST   D3S1358: 16
ST   D5S818: 14
ST   D7S820: 8,11
ST   D8S1179: 10,11
ST   FGA: 20,23
ST   Penta D: 9,11
ST   Penta E: 12,15
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2994 ! KMS-28BM
SX   Female
AG   77Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 14-08-25; Version: 34
//
RX   CelloPub=CLPUB00604;
RA   Chow, Sharon
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017); University of Toronto; Toronto; Canada.
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn, Christiaan
RA   Durinck, Steffen
RA   Stawiski, Eric W.
RA   Haverty, Peter M.
RA   Jiang, Zhao-Shi
RA   Liu, Han-Bin
RA   Degenhardt, Jeremiah
RA   Mayba, Oleg
RA   Gnad, Florian
RA   Liu, Jin-Feng
RA   Pau, Gregoire
RA   Reeder, Jens
RA   Cao, Yi
RA   Mukhyala, Kiran
RA   Selvaraj, Suresh K.
RA   Yu, Ma-Mie
RA   Zynda, Gregory J.
RA   Brauer, Matthew J.
RA   Wu, Thomas D.
RA   Gentleman, Robert Clifford
RA   Manning, Gerard
RA   Yauch, Robert L.
RA   Bourgon, Richard
RA   Stokoe, David
RA   Modrusan, Zora
RA   Neve, Richard M.
RA   de Sauvage, Frederic J.
RA   Settleman, Jeffrey
RA   Seshagiri, Somasekar
RA   Zhang, Ze-Min
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1; PMCID=PMC7483300;
RA   Sarin, Vishesh
RA   Yu, Katharine
RA   Ferguson, Ian D.
RA   Gugliemini, Olivia
RA   Nix, Matthew A.
RA   Hann, Byron
RA   Sirota, Marina
RA   Wiita, Arun P.
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003; PMCID=PMC2083698;
RA   Keats, Jonathan J.
RA   Fonseca, Rafael
RA   Chesi, Marta
RA   Schop, Roelandt
RA   Baker, Angela
RA   Chng, Wee-Joo
RA   Van Wier, Scott
RA   Tiedemann, Rodger
RA   Shi, Chang-Xin
RA   Sebag, Michael
RA   Braggio, Esteban
RA   Henry, Travis
RA   Zhu, Yuan-Xiao
RA   Fogle, Homer
RA   Price-Troska, Tammy L.
RA   Ahmann, Gregory J.
RA   Mancini, Catherine
RA   Brents, Leslie A.
RA   Kumar, Shaji K.
RA   Greipp, Philip Robert
RA   Dispenzieri, Angela
RA   Bryant, Barb
RA   Mulligan, George
RA   Bruhn, Laurakay
RA   Barrett, Michael T.
RA   Valdez, Riccardo
RA   Trent, Jeffrey M.
RA   Stewart, A. Keith
RA   Carpten, John D.
RA   Bergsagel, Peter Leif
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers, Jelle
RA   Boegel, Sebastian
RA   Bukur, Thomas
RA   Byl, Marius
RA   Goerges, Sebastian
RA   Sorn, Patrick
RA   Loewer, Martin
RA   Sahin, Ugur
RA   Castle, John C.
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011; PMCID=PMC2737184;
RA   Dib, Amel
RA   Gabrea, Ana
RA   Glebov, Oleg K.
RA   Bergsagel, Peter Leif
RA   Kuehl, Walter Michael
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2; PMCID=PMC1618545;
RA   Inoue, Jun
RA   Otsuki, Takemi
RA   Hirasawa, Akira
RA   Imoto, Issei
RA   Matsuo, Yoshinobu
RA   Shimizu, Shiroh
RA   Taniwaki, Masafumi
RA   Inazawa, Johji
RT   "Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be
RT   associated with drug-resistance phenotype in multiple myeloma.";
RL   Am. J. Pathol. 165:71-81(2004).
//